MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012.
MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®.
MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD).
MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)”
PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals.
MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).
Company Details
- Employees
- 8
- Founded
- -
- Address
- 분당구 대왕판교로644번길 21, 성남시,경기도,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.medi-post.co.kr/
- HQ
- 성남시, 경기도
Medipost (Subsidiary Company_evastem) Questions
Medipost (Subsidiary Company_Evastem)'s website is http://www.medi-post.co.kr/
Medipost (Subsidiary Company_Evastem)'s LinkedIn profile is https://kr.linkedin.com/company/medi-post
Medipost (Subsidiary Company_Evastem) has
8 employees.
View email and phone details for 8
employees at Medipost (Subsidiary Company_Evastem).
Medipost (Subsidiary Company_Evastem)'s industry is
Biotechnology Research
Medipost (Subsidiary Company_Evastem)'s top competitors are
Takeda,
Medipost,
(주)온코인사이트 / Oncoinsight Co., Ltd.,
Immuse Therapeutics, Inc.,
Autotac Bio Inc.,
Medipost Co Ltd,
Omniabio,
Janux Therapeutics,
Medipost Holdings,
Medipost, Inc..
Medipost (Subsidiary Company_Evastem)'s categories are Biotechnology Research
Medipost (Subsidiary Company_Evastem)'s founding year is 2000
